Trial Profile
A phase 3, randomized, double-blind, active controlled, multicenter trial to evaluate the safety and efficacy of muraglitazar (BMS-298585) compared to pioglitazone in subjects with type 2 diabetes who have inadequate glycemic control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Muraglitazar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 14 Feb 2006 New trial record.